Osteoarthritis
Conditions
Keywords
LT-NS001, Gastric Ulcers, NSAID, Osteoarthritis, Naproxen
Brief summary
LT-NS001 is a prodrug of Naproxen, which is inactive as a cox inhibitor while intact and is rapidly metabolized to Naproxen once absorbed. This trial will compare the rate of gastric ulcer by endoscopy over three months in patients with knee osteoarthritis, with patients receiving either LT-NS001 at a dose which provides comparable dose levels of Naproxen, or Naprosyn® 500mg (an approved treatment for OA).
Detailed description
This is a double-blind, double-dummy, active-comparator study of LT-NS001 versus Naprosyn® for 12 weeks in patients aged 45-80 with osteoarthritis of the knee who are candidates for ongoing NSAID therapy. The percentage of patients with a gastric ulcer by endoscopy (EGD) at week 12 will be compared. EGD is performed at screening and months 1, 2, and 3. Secondary objectives include assessment of pain in the affected knee by WOMAC questionnaire to demonstrate non-inferior pain control using LT-NS001 as compared to Naprosyn®. Information about gastrointestinal pain and tolerability will be collected. The length of the study is up to 19 weeks with a 2-3 week screening period, a 12 week treatment period and a 4 week post treatment monitoring period.
Interventions
Sponsors
PRA Health Sciences
Logical Therapeutics
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
ALL
Age
45 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Osteoarthritis of knee * Appropriate candidate for chronic NSAID therapy due to moderate or severe pain on most days in the 28 days before screening for study.
Exclusion criteria
* Pregnant/Nursing women * History of GI bleeding, perforation or obstruction * A documented symptomatic GI ulcer during past 5 years * Presence of GI ulcer or more than 2 erosions on screening endoscopy * Allergy to naproxen (or naproxen intolerance), acetylsalicylic acid, or other NSAID drug
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gastric Ulcer by Endoscopy | Baseline, Day 29, Day 57 and Day 85 |
Secondary
| Measure | Time frame |
|---|---|
| Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score | Screening, Baseline, Days 15, 29, 57 and 85 |
| Population pharmacokinetic analysis will assess the influence of covariates on the absorption/metabolism of LT-NS001 to naproxen | Two separate days after Day 14, at least two weeks apart |
Countries
United States
Outcome results
None listed